Transaction #3516 · Form 4 · 0001276750-25-000004
X4 Pharmaceuticals, Inc · Stock award · Stock Option (right to buy)
X4 Pharmaceuticals, Inc · Transacted October 29, 2025 · Filed October 31, 2025
What does this filing report?
An SEC Form 4 filing for X4 Pharmaceuticals, Inc records a stock award involving Stock Option (right to buy) on October 29, 2025. The reported quantity was 1,552,769. The filing date is October 31, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- X4 Pharmaceuticals, Inc
- Company CIK
- 0001501697
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 1,552,769
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,552,769
- Ownership description
- Not reported
- SEC acceptance time
- Oct 31, 2025, 4:41 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- KIRSKE DAVID ↗
Chief Financial Officer
CIK 0001276750
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 1,552,769
- Conversion / exercise price
- 1.42
- Exercise date
- Not reported
- Expiration date
- August 12, 2035
Filing footnotes & remarks
- F1
- Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.